Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Tumour Cells Europe

Daniel Danila's Biography

Daniel Danila, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Centre

Dr Danila is a board-certified medical oncologist and is part of a multidisciplinary team that provides compassionate and expert care to patients with prostate cancer and other genitourinary malignancies. Himself and his colleagues provide patients with individualized treatment approaches that include novel hormonal agents and biologics along with advanced diagnostic methods to ensure that patients receive the most effective treatment and have the best possible outcome.

Dr Danila's laboratory research is focused on identifying biomarkers in prostate cancer that can help doctors select the most effective approach for each individual. His research is also focused on accelerating the pace at which laboratory discoveries are brought to the clinic. In related clinical studies he is investigating whether it is possible to use biologic profiles of androgen receptor signaling in patients’ tumor cells to predict their response to treatment.

Dr Danila is an author of numerous studies in these areas, and received a Young Investigator Award and two Merit Awards from the American Society of Clinical Oncology, and a Physician Research Training Award from the Department of Defense.

Daniel Danila Image

Biomarkers in Circulating Tumor Cells: Current Progress Toward Qualifying Molecular Assays

Thursday, 10 May 2012 at 09:30

Add to Calendar ▼2012-05-10 09:30:002012-05-10 10:30:00Europe/LondonBiomarkers in Circulating Tumor Cells: Current Progress Toward Qualifying Molecular

Unmet needs in cancer drug development and patient management are the ability to monitor treatment benefit and to identify the target of interest in a tumor at the time treatment is being considered. Focusing on molecular biomarkers in CTC, this presentation will emphasize the current state of establishing analytical valid biomarkers for specific contexts of use in patients with castration-resistant prostate cancer.

Add to Calendar ▼2012-05-10 00:00:002012-05-11 00:00:00Europe/LondonCirculating Tumour Cells